Open Access<sup>18</sup>F-FDG PET/CT Showing Rare Mediastinal Growing Teratoma Syndrome Following Chemotherapy
Author(s) -
Mihoko Sasahara,
Takashi Abe,
Yoichi Otomi,
Yumi Abe,
Hiroaki Toba,
Takayoshi Shinya,
Hideki Otsuka,
Masafumi Harada
Publication year - 2022
Publication title -
molecular imaging and radionuclide therapy
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.292
H-Index - 7
eISSN - 2147-1959
pISSN - 2146-1414
DOI - 10.4274/mirt.galenos.2021.54775
Subject(s) - medicine , germ cell tumors , chemotherapy , nuclear medicine , human chorionic gonadotropin , positron emission tomography , mature teratoma , hormone
Growing teratoma syndrome (GTS) is a condition in which poorly differentiated cells in a mixed-germ cell tumor (GCT) regress after chemotherapy, and the number of well-differentiated components increases. A 60-year-old man had an 8.0 cm mediastinal tumor with strong 18 F-fluorodeoxyglucose (FDG) uptake [maximum standardized uptake value (SUV max ): 9.2], which was diagnosed as a GCT. After chemotherapy, serum alpha fetoprotein, beta-human chorionic gonadotropin, and tumor 18 F-FDG uptake decreased (SUV max : 3.9), but the tumor volume increased. The tumor was completely resected, and pathology confirmed the diagnosis of GTS. 18 F-FDG positron emission tomography after chemotherapy reflects the proliferation of highly differentiated tumor components with poor 18 F-FDG uptake.